title: CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report.
abstract: Between March 1987 and December 1988, 30 previously untreated patients with low-grade non-Hodgkin's lymphomas (NHL), according to the Kiel classification, were treated by a combination of therapy including cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP). Eighteen patients (60%) achieved a complete pathologic remission, and 8 patients (26.6%) had a partial response with a reduction of more than 50% of tumor-related manifestations. Four patients (13.4%) were primary resistant to CEOP. The overall survival was 96.6% with a median follow-up of 25 months from the diagnosis; none of the patients who achieved complete response relapsed at a median follow-up of 21 months from the completion of treatment. Clinical and hematologic toxicities were irrelevant. This regimen was effective in inducing a good remission rate of low-grade NHL, but a longer follow-up for definitive conclusions is warranted.
authors.affiliation: Institute of Hematology L. e A. Sergnoli, University of Bologna, Italy.
authors.forename: P L
authors.initials: PL
authors.lastname: Zinzani
authors.forename: P
authors.initials: P
authors.lastname: Mazza
authors.forename: F
authors.initials: F
authors.lastname: Gherlinzoni
authors.forename: R
authors.initials: R
authors.lastname: Zanchini
authors.forename: M
authors.initials: M
authors.lastname: Bocchia
authors.forename: E
authors.initials: E
authors.lastname: Aitini
authors.forename: G
authors.initials: G
authors.lastname: Cavazzini
authors.forename: B
authors.initials: B
authors.lastname: Amurri
authors.forename: M
authors.initials: M
authors.lastname: Gobbi
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015251:Epirubicin; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone